CytomX Therapeutics (CTMX) Revenue (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Revenue came in at $10.3 million in Q1 2026, down 79.85% YoY from $50.9 million in Q1 2025, and up 1447.21% on a QoQ basis from $663000.0 in Q4 2025.
CytomX Therapeutics (CTMX) Revenue (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Revenue data on file, last reported at $10.3 million in Q1 2026.
- Quarterly Revenue fell 79.85% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.5 million (down 75.91% YoY) and the FY2025 annual result came in at $76.2 million, down 44.82% from the prior year.
- Revenue grew to $10.3 million in Q1 2026, from $663000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $50.9 million in Q1 2025 to a low of $663000.0 in Q4 2025.
- A 5-year average of $22.3 million and a median of $23.5 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue jumped 159.94% — and 2025, when it slumped 98.26%.
- Tracing CTMX's Revenue over 5 years: stood at $20.1 million in 2022, then jumped by 32.22% to $26.6 million in 2023, then surged by 43.17% to $38.1 million in 2024, then tumbled by 98.26% to $663000.0 in 2025, then surged by 1447.21% to $10.3 million in 2026.
- The last three Revenue figures came in at $10.3 million (Q1 2026), $663000.0 (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 1.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.42 Mn |
| Mar 31, 2026 | 10.26 Mn |
| Dec 31, 2025 | 663,000.00 |
| Sep 30, 2025 | 5.96 Mn |
| Jun 30, 2025 | 18.66 Mn |
| Mar 31, 2025 | 50.92 Mn |
| Dec 31, 2024 | 38.09 Mn |
| Sep 30, 2024 | 33.43 Mn |
| Jun 30, 2024 | 25.12 Mn |
| Mar 31, 2024 | 41.46 Mn |
| Dec 31, 2023 | 26.61 Mn |
| Sep 30, 2023 | 26.38 Mn |
| Jun 30, 2023 | 24.72 Mn |
| Mar 31, 2023 | 23.50 Mn |
| Dec 31, 2022 | 20.12 Mn |
| Sep 30, 2022 | 11.15 Mn |
| Jun 30, 2022 | 12.85 Mn |
| Mar 31, 2022 | 9.04 Mn |
| Dec 31, 2021 | 11.13 Mn |
| Sep 30, 2021 | 9.19 Mn |